GSK, RSV and Shingles
GSK's RSV, Shingles vaccines show on-par immune response in joint trial
British drugmaker GSK said on Wednesday administration of its respiratory syncytial virus (RSV) vaccine and shingles shot together generated the same immune response in a late-stage trial as separate adminstration of the vaccines.
GSK Builds Combo Case for RSV, Shingles Shots With Phase III Data
If approved, the co-administration of Arexvy and Shingrix could provide a more convenient vaccination regimen for patients and potentially bolster GSK’s faltering sales for both vaccines.
GSK Meets Study Goal for Co-Administered RSV-Shingles Vaccines
GSK plc GSK announced positive topline results from a phase III study evaluating the co-administration of its two marketed vaccines — RSV vaccine Arexvy and shingles vaccine Shingrix — in older adults (aged 50 years and older).
GSK's experimental herpes vaccine fails to meet main goal in trial
British drugmaker GSK said on Wednesday its experimental herpes simplex virus (HSV) vaccine candidate failed to meet the main goal of a mid-stage trial and would not be taken forward to a late-stage trial.
GSK posts late-stage trial win for co-administered RSV and shingles vaccines
GSK (NYSE:GSK) announced Wednesday that its Arexvy vaccine for respiratory syncytial virus (RSV) and its Shingrix vaccine for shingles reached the main goal in a Phase 3 trial when they were co-administered in adults aged 50 and older.
GSK Reports Positive Data From Co-administration Of RSV And Shingles Vaccines
GSK plc (GSK, GSK.L) announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the
GSK Sees Positive Results in Trial of Combination RSV, Shingles Vaccine
GSK recorded positive topline data in a late stage trial of its respiratory syncytial virus vaccine combined with a shingles vaccine in treating adults 50 years and older. The British pharma giant said Wednesday a Phase 3 study evaluating RSV vaccine Arexvy co-administered with Shingrix met the primary endpoint,
legit3d
After GSK, Sanofi Exit, Another Multinational Company Set to Leave Nigeria, Gives Reasons
PZ Cussons has decided to leave Nigeria, citing naira's devaluation as the reason after GSK, Sanofi and other multinationals ...
GSK (LSE:GSK) Poised for Growth with Strong Sales, Strategic Alliances, and New Vaccine Launches
GSK(LSE:GSK) is navigating a dynamic environment marked by both opportunities and challenges. Recent highlights include a ...
GlaxoSmithKline Sell Rating Justified by Earnings Concerns and Market Challenges
Bank of America Securities analyst Graham Parry maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) yesterday and set a ...
Joplin Globe4d
GSK Announces Positive Topline Data on Co-Administration of AREXVY and SHINGRIX
GSK plc (LSE/NYSE: GSK) today announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, reactogenicity and safety of AREXVY (Respiratory ...
GSK says mRNA flu shot shows promise in boost for pipeline
GSK Plc’s experimental mRNA flu vaccine showed a positive immune response against two key types of flu viruses in a mid-stage trial.
GSK Settles 2 Cases In California Against Zantac
Drug maker GSK plc (GSK, GSK.L) confirmed Wednesday that it has reached two confidential settlements in cases filed in California ...
Is the GSK share price the biggest bargain on the FTSE 100?
The GSK share price is nearly 10% off its 52-week high, and this Fool is keen to take a closer look. Could it be a stock for ...
Yahoo Finance13d
With GSK’s share price down 9%, is it time for me to buy more on the dip?
On several key measures of the fundamental soundness of a business, GSK looks in great shape to me. Over the first half of this year, sales rose 12%, to £15.247bn. Core operating profit jumped 22% ...
Morningstar4d
GSK Announces Positive Topline Data on Co-Administration of AREXVY and SHINGRIX
Len Friedland, MD, Vice President of Scientific Affairs and Public Health, GSK, said: “We are excited to share data on the co‑administration of our RSV and shingles vaccines. Adult ...